Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential PCV13 + PPSV23 vs PPSV23 Alone in Immunocompromised Adults (CPI Study)
jRCTs031180147Completed
- Sponsor
- National Hospital Organization
- Start
- Feb 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in Pneumococcal pneumonia (PP), pneumococcal disease, invasive pneumococcal disease (IPD) and 1 more comparing Sequential PCV13 then PPSV23 with Single PPSV23 (2 arms). Primary endpoint: Incidence of pneumococcal pneumonia. Started Feb 2019; status: completed.
02
Drugs
Prevnar 1323-valent pneumococcal polysaccharide vaccine
03
Conditions
Pneumococcal pneumonia (PP)pneumococcal diseaseinvasive pneumococcal disease (IPD)pneumonia
Beyond the preview
Go deeper on jRCTs031180147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180147.